|
Oct 9
|
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
|
|
Oct 7
|
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
|
|
Aug 30
|
Gain Therapeutics reports positive data from Phase I Parkinson’s treatment trial
|
|
Aug 29
|
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
|
|
Jun 25
|
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
|
|
Jun 14
|
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
|
|
Jun 13
|
Gain Therapeutics Announces Proposed Public Offering
|
|
May 14
|
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
|
|
May 3
|
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
|
|
Apr 24
|
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
|
|
Apr 17
|
Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
|
|
Apr 10
|
Insiders are Piling into These 10 Healthcare Stocks in 2024
|
|
Apr 10
|
Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)
|
|
Apr 9
|
Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?
|
|
Apr 8
|
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
|
|
Apr 1
|
Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)
|
|
Apr 1
|
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
|
|
Mar 26
|
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
|
|
Mar 15
|
Gain Therapeutics to Present at Public Ventures Discovery Day
|
|
Mar 5
|
EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease
|